Yuanzhi Powder inhibits tau pathology in SAMP8 mice: Mechanism research of a traditional Chinese formula against Alzheimer's disease

Li, Bin; Li, Jiaxin; Hao, Yanwei; Xie, Pei-Jun; Yue, Shengnan; Wang, Shaofeng; Zhang, Jing; Zhang, Yi

doi:10.1016/j.jep.2023.116393

Cited by 5 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathomechanism of AD is complex, and numerous studies have been conducted but still have not led to drugs and targets that can effectively delay the progression of the disease (Ferrari and Sorbi, 2021;Passeri et al, 2022b). TCM formulas with PT as the principal drug have been repeatedly shown to improve cognitive symptoms in AD by consistently regulating phosphorylated tau (Qu et al, 2021;Li et al, 2023). AT has also been implicated in the therapeutic potential of AD by modulating the BDNF/ERK/CREB signaling pathway and the synapse-associated protein PSD-95 (Ning et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Polygala tenuifolia and Acorus tatarinowii in the treatment of Alzheimer’s disease: a systematic review and meta-analysis

Zhang,

Tian,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Background: The complexity of Chinese medicine treatment for Alzheimer’s disease (AD) utilizing a multi-herb therapy makes the evidence in current studies insufficient. Herb pairs are the most fundamental form of multi-herb formulae. Among the Chinese herbal formulas for AD treatment, Polygala tenuifolia (PT) and Acorus tatarinowii (AT) appeared as the most commonly used herbal pairs in combination.Objective: The aim of this study is to evaluate the clinical efficacy and safety of the combination of PT and AT in the treatment of AD.Methods: We systematically searched and screened randomized controlled trials of pairing PT and AT for the treatment of AD patients in eight databases with a search deadline of June 26, 2023. Authors, year of publication, title, and basic information such as subject characteristics (age, sex, and race), course of disease, control interventions, dose, and treatment duration were extracted from the screened studies. Primary outcomes assessed included mini-mental state examination (MMSE), activities of daily living (ADL), and AD assessment scale-cognitive subscale (ADAS-cog), while secondary outcomes included efficiency and adverse events. The quality of the included studies was assessed using the Cochrane risk of bias tool. The mean difference with 95% confidence intervals (MD [95% CI]) and risk ratio (RR) was selected as the effect size, and the data were analyzed and evaluated using RevMan 5.4 and Stata 16.Results: A total of sixteen eligible and relevant studies involving 1103 AD participants were included. The combination of PT and AT plus conventional drugs was superior to single conventional drugs in MMSE [MD = 2.57, 95%CI: (1.44, 3.69); p < 0.00001; I2 = 86%], ADL [MD = −3.19, 95%CI: (−4.29, −2.09); p < 0.00001; I2 = 0%], and ADAS-cog scores [MD = −2.09, 95%CI: (−3.07, −1.10); p < 0.0001; I2 = 0%]. The combination of PT and AT plus conventional drugs had a significantly more favorable benefit in clinical effectiveness [RR = 1.27, 95%CI: (1.12, 1.44); p = 0.0002; I2 = 0%]. Adverse events were not increased with the combination of PT and AT plus conventional drugs compared to conventional drugs [RR = 0.65, 95%CI: (0.35, 1.19); p = 0.16; I2 = 0%]. The experimental group treated with the combination of PT and AT alone for AD was comparable in MMSE, ADL, and ADAS-cog scores compared with the control group treated with single conventional drugs.Conclusion: Compared to single conventional drugs, the combination of PT and AT may be used as an alternative therapy to improve global cognition and functioning in AD, and the combination of PT and AT as adjunctive therapy appears to produce a better therapeutic response to AD in terms of efficacy without increasing the risk of adverse events. However, the very low to low quality of available evidence limits confidence in the findings.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/, identifier CRD42023444156.

show abstract